You are here

Novel HER3 Antibody in the Treatment of Cancer

Technology Number: 

1773

Principal Investigator

Prof.
Yosef
Yarden

Department: 

Biological Regulation
Summary 

Treatment of multiple types of oncological malignancies, such as breast cancer involves the targeting one the of HER (EGFR/ErbB) family receptor tyrosine kinases. The challenge that arises in using a specific HER receptor for therapeutic applications is that the cancer can develop resistance to said treatment. This tolerance arises due to compensatory mechanisms, such as the activation of alternate HER receptors. Consequently, there is a strong need to develop treatments that target HER receptors outside of the ubiquitously targeted HER1 and 2. In many cases it is HER3 which is responsible for such emergence of resistance.

The group of Prof. Yosef Yarden have developed a novel high affinity anti-HER3 antibody, to act either as an individual anti-cancer treatment or in combination with other therapies.  

Applications


  •  Cancer therapy

  •  Diagnostic tool


Technology's Essence


Prof. Yarden’s research group has developed a high affinity anti-HER3 antibody with a Kd in the range of 10 nM. The group tested the effectiveness of the antibody (termed N33) both in vitro and in xenografts. In all tested cases the anti-HER3 antibody showed promising effects in stopping cancer cell line growth and reducing tumor volume in mouse models.

More technologies in Biotechnology, Pharma and Diagnostics